Expert Examines Emerging Biomarkers in NSCLC

Brandon Weckbaugh, MD, an oncology fellow at UMKC is interview on OncLive
The treatment landscape of non–small cell lung cancer (NSCLC) continues to expand with potential biomarkers that are under investigation, as well as novel agents that could potentially target them. What was once a major area of unmet need has experienced an explosion of new research, said Brandon Weckbaugh, MD. Read the interview.

Learn more about School of Medicine

Published: Jan 22, 2019

Top Stories